Loading clinical trials...

COMPLETEDNA

Characteristics of Treatment Responders to Galantamine

Characteristics of Treatment Responders to Galantamine Administration in the Patients With Alzheimer's Disease

NCT01029132•Samsung Medical Center

View on ClinicalTrials.gov

Summary

To investigate the characteristics of treatment responders to galantamine.

Detailed Description

The purposes of this study are: 1. to investigate the characteristics of treatment responders to galantamine by examining the clinical response of galantamine in patients with mild to moderate AD for 52 weeks. 2. to examine the specific cognitive sub-domains that are more sensitive to galantamine administration.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. A diagnosis of probable AD according to the criteria of the NINCDS-ADRDA
•2. Korean version Mini-Mental State Examination scores between 10 and 26
•3. History of cognitive decline that had been gradual in onset and progressive over at least 6 months
•4. A caregiver who could assist the patient with medication, attend the assessment and provide information about the patient.

Exclusion Criteria

•1. they had evidence of any neurodegenerative diseases other than AD (i.e. Parkinson's disease, Huntington's disease)
•2. Psychiatric disorder or severe behavioral disturbances that required psychotropic medications
•3. Cerebral injuries induced by trauma, hypoxia, and/or ischemia
•4. Clinically active cerebrovascular disease; History of seizure disorder
•5. Other physical conditions that required acute treatment.

Locations (1)

Samsung Medical Center

Seoul, South Korea

Key Dates

Start Date

April 1, 2007

Primary Completion Date

October 1, 2009

Completion Date

October 1, 2009

Last Updated

January 6, 2016

Enrollment

ACTUAL participants

Conditions

Dementia

Interventions

galantamine

DRUG

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGPHASE3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789

Alzheimer DiseaseDementia+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 6, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Characteristics of Treatment Responders to Galantamine

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Testing the Pain Clinical Practice Guideline

Circadian Rhythm and Other Factors in Memory Clinic Patients

Neurocognitive Assessment Platform 4 Alzheimer